Authors: Jade Parker, Editor & Joseph Martin, Future Science Group
In this breast cancer news round-up we highlight the most notable drug approvals and research advancements that have emerged over the week.
Palbociclib and ribociclib given the green light for routine NHS use
Palbociclib and ribociclib have been approved for use on the NHS for individuals with hormone receptor positive, human epidermal growth factor receptor 2 negative locally advanced or secondary breast cancer; following the release of draft guidance from NICE.
The committee found that both palbociclib and ribociclib stalled the growth of the cancer for an extra 10 months on average and concluded that it was likely that this would result in some improvement in overall survival, although this could not be quantified from the current clinical trials.
“The development of this brand new class of cancer drug is one of the most important breakthroughs for women with advanced breast cancer in the last two decades,” Nicholas Turner, one of the clinical experts on the NICE panels for both drugs and led the PALOMA-3 trial from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust (both London, UK) commented. 
Click here to find out more about palbociclib in an article from Future Oncology.
Breast cancer can resurface 15 years after treatment
An international group of researchers have discovered that even 20 years after a diagnosis, women ER-positive breast cancer still face a substantial risk of cancer recurrence or spread. The results were published recently in the New England Journal of Medicine.